Anticoagulant Reversal Drugs Market Scope And Analysis

  • Report Code : TIPRE00004954
  • Category : Pharmaceuticals
  • No. of Pages : 150
Buy Now

Anticoagulant Reversal Drugs Market Scope and Analysis by 2031

Buy Now

Anticoagulant Reversal Drugs Market Report Anticoagulant Reversal Drugs Market Size and Share Anticoagulant Reversal Drugs Market Scope and Analysis

Anticoagulant Reversal Drugs Market Report Scope

Report Attribute Details
Market size in 2023 US$ 1306.40 Million
Market Size by 2031 US$ 2,442.87 Million
Global CAGR (2023 - 2031) 10.08%
Historical Data 2021-2022
Forecast period 2024-2031
Segments Covered By Product
  • Prothrombin Complex Concentrates
  • Vitamin K
  • Protamine
  • Tranexamic Acid
  • Idarucizumab
  • AndeXXa
By Product
  • Prothrombin Complex Concentrates
  • Vitamin K
  • Protamine
  • Tranexamic Acid
  • Idarucizumab
  • AndeXXa
Regions and Countries Covered North America
  • US
  • Canada
  • Mexico
Europe
  • UK
  • Germany
  • France
  • Russia
  • Italy
  • Rest of Europe
Asia-Pacific
  • China
  • India
  • Japan
  • Australia
  • Rest of Asia-Pacific
South and Central America
  • Brazil
  • Argentina
  • Rest of South and Central America
Middle East and Africa
  • South Africa
  • Saudi Arabia
  • UAE
  • Rest of Middle East and Africa
Market leaders and key company profiles
  • Sanofi
  • Johnson Johnson
  • Glaxosmithkline
  • Bausch Health
  • Takeda Pharmaceuticals
  • Lexicon Pharmaceuticals Inc
  • Takeda Pharmaceuticals
  • AbbVie Inc

    • Anticoagulant Reversal Drugs Market News and Recent Developments

    The anticoagulant reversal drugs market is evaluated by gathering qualitative and quantitative data from primary and secondary research, which includes important corporate publications, association data, and databases. The following is a list of developments in the market for speech and language disorders and strategies:

    • AstraZeneca Pharma India Ltd. announced that it received approval from the Central Drugs Standard Control Organisation (CDSCO) in India to import and market Andexanet Alfa. This treatment is effective in addressing life-threatening or refractory bleeding that comes with the use of Factor Xa (FXa) inhibitors. (Source: AstraZeneca Pharma, Press Release, 2024)
    • Octapharma USA announced the approval of Balfaxar from the US Food and Drug Administration (FDA). Balfaxar is a non-activated four-factor prothrombin complex concentrate (4F-PCC) containing vitamin K-dependent factors: Factor II (prothrombin), Factor VII, Factor IX, and Factor X, and antithrombotic Proteins C and S. It can be used to urgently reverse acquired coagulation factor deficiency induced by vitamin K antagonist (VKA) therapy in adult patients who require urgent surgery or invasive procedures. Balfaxar helps restore blood coagulation by replenishing the levels of deficient clotting factors due to warfarin therapy. (Source: Octapharma USA, Inc, Press Release, 2023)

    Anticoagulant Reversal Drugs Market Report Coverage and Deliverables

    The “Anticoagulant Reversal Drugs Market Size and Forecast (2021–2031)” report provides a detailed analysis of the market covering below areas:

    • Market size and forecast at global, regional, and country levels for all the key market segments covered under the scope
    • Market dynamics such as drivers, restraints, and key opportunities
    • Key future trends
    • Detailed PEST/Porter’s Five Forces and SWOT analysis
    • Global and regional market analysis covering key market trends, major players, regulations, and recent market developments
    • Industry landscape and competition analysis covering market concentration, heat map analysis, prominent players, and recent developments
    • Detailed company profiles